[The effect of antisense hsp90 beta on the malignant phenotype and sensitivity of HeLa cells to chemotherapeutic drugs].
OBJECTIVE
To study the effects of hsp90 beta on tumorigenesis and sensitivity of HeLa cells to chemotherapeutic drugs.


METHODS
A recombinant plasmid expressing either sense or antisense hsp90 beta RNA, and a vector pLXSN were transfected into HeLa cell line by lipofectin method. The transfected cells were screened by G418. The growth rates of the transfected HeLa cells and their sensitivity to adriamycin(ADM) and cisplatin (CDDP) were examined by cell count and MTT uptake. Colony formation in soft agar was used to embody the malignant phenotype in vitro.


RESULTS
There was little difference between HeLa cells transfected with sense RNA plasmids and pLXSN vector. The growth rate of HeLa cells transfected with antisense RNA declined, and their ability to form colony in soft agar was decreased. The sensitity of the antisense hsp90 beta transfected HeLa cells to ADM and CDDP increased 2.1-5.8 fold; the LD50 decreased to 1/2-1/5 that of the wild-type HeLa cells.


CONCLUSIONS
Hsp90 beta is involved in the maintenance of malignant phenotype and drug resistance in HeLa cells.
Huang
C
C
Cancer Institute (Hospital), Chinese Academy Medical Science, Peking Union Medical College, Beijing 100021, China.
Zhou
C
C
Zhao
M
M
D000970:Antineoplastic Agents / Q000494:pharmacology*; D015197:Carcinogenicity Tests; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000235:genetics / Q000502:physiology; D004354:Drug Screening Assays, Antitumor; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D006367:HeLa Cells / Q000187:drug effects*; D006801:Humans; D020128:Inhibitory Concentration 50; D010641:Phenotype; D016372:RNA, Antisense / Q000494:pharmacology*; D014162:Transfection / Q000379:methods
D000970:Antineoplastic Agents; D018841:HSP90 Heat-Shock Proteins; D016372:RNA, Antisense; D004317:Doxorubicin; D002945:Cisplatin